PA
SRNE

Pinnacle Associates’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Pinnacle Associates’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,700
Closed -$53K – 641
2014
Q3 		$53K Hold
11,700
– – ﹤0.01% 616
2014
Q2 		$79K Buy
+11,700
New +$88.2K ﹤0.01% 602

Other funds holding SRNE

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.39% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pinnacle Associates's SRNE Position: Q4 2014 in Review

Pinnacle Associates sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2014, closing a stake of 11,700 shares — an estimated $53K sold.

Pinnacle Associates first reported a position in SRNE in Q2 2014 and held it in 2 quarters. The position peaked at $79K in Q2 2014. 38 funds tracked by Wall St. Rank hold SRNE as of Q4 2014.

  • Pinnacle Associates reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Pinnacle Associates sold 11,700 Sorrento Therapeutics, Inc. shares in Q4 2014, an estimated $53K.
  • Pinnacle Associates first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
  • Pinnacle Associates's Sorrento Therapeutics, Inc. position peaked at $79K in Q2 2014.
  • 38 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2014.

Based on Pinnacle Associates's 13F filing for Q4 2014, filed 12 Feb 2015.